Gate2brain
Biotech company improving drug delivery to the brain using a peptide-based patented technology. Learn more
Launch date
Employees
Company register number B01697564
Barcelona Catalonia (HQ)
Financials
Estimates*
| EUR | 2020 | 2021 |
|---|---|---|
| Revenues | - | <1m |
| EBITDA | (<1m) | (<1m) |
| % EBITDA margin | - | (827 %) |
| Profit | (<1m) | (<1m) |
| % profit margin | - | (180 %) |
| Date | Investors | Amount | Round |
|---|---|---|---|
€100k | Grant | ||
€500k | - | ||
N/A | Spinout | ||
N/A | Spinout | ||
| N/A | €100k | - | |
N/A | Grant | ||
* | €2.5m | Grant | |
N/A | Early VC | ||
| Total Funding | AUD5.4m | ||
Related Content
Recent News about Gate2brain
EditMore about Gate2braininfo icon
EditDeveloper of a novel technology platform intended for the delivery of therapeutics across biological barriers. The company focuses on the development of therapeutics that efficiently cross biological barriers such as the blood-brain barrier using a radically innovative peptide-based patented technology platform, enabling the medical industry to cure rare pediatric cancers.
Keywords: Pharmaceuticals and Biotechnology, Anticancer Drug Delivery, Biotech Company, Brain Disease Treatment, Drug Delivery System, Drug Delivery Technology, Pediatric Cancer.
Tech stack
Tech stackLearn more about the technologies and tools that this company uses.